CN1243540C - 用于治疗阿尔茨海默氏型老年性痴呆的活性组分的组合 - Google Patents

用于治疗阿尔茨海默氏型老年性痴呆的活性组分的组合 Download PDF

Info

Publication number
CN1243540C
CN1243540C CNB988130947A CN98813094A CN1243540C CN 1243540 C CN1243540 C CN 1243540C CN B988130947 A CNB988130947 A CN B988130947A CN 98813094 A CN98813094 A CN 98813094A CN 1243540 C CN1243540 C CN 1243540C
Authority
CN
China
Prior art keywords
alkyl
compound
tetrahydropyridine
group
trifluoromethylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988130947A
Other languages
English (en)
Chinese (zh)
Other versions
CN1285742A (zh
Inventor
J·－P·马夫兰德
P·索布里
J·－P·特拉诺瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9714324A external-priority patent/FR2771006B1/fr
Priority claimed from FR9714322A external-priority patent/FR2771007B1/fr
Application filed by Sanofi Synthelabo SA, Sanofi Aventis France filed Critical Sanofi Synthelabo SA
Publication of CN1285742A publication Critical patent/CN1285742A/zh
Application granted granted Critical
Publication of CN1243540C publication Critical patent/CN1243540C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNB988130947A 1997-11-14 1998-11-09 用于治疗阿尔茨海默氏型老年性痴呆的活性组分的组合 Expired - Fee Related CN1243540C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9714324A FR2771006B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer
FR9714322A FR2771007B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer
FR97/14324 1997-11-14
FR97/14322 1997-11-14

Publications (2)

Publication Number Publication Date
CN1285742A CN1285742A (zh) 2001-02-28
CN1243540C true CN1243540C (zh) 2006-03-01

Family

ID=26233932

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988130947A Expired - Fee Related CN1243540C (zh) 1997-11-14 1998-11-09 用于治疗阿尔茨海默氏型老年性痴呆的活性组分的组合

Country Status (27)

Country Link
EP (1) EP1030671A1 (fr)
JP (1) JP2001523642A (fr)
KR (1) KR100599350B1 (fr)
CN (1) CN1243540C (fr)
AU (1) AU743228B2 (fr)
BG (1) BG64819B1 (fr)
BR (1) BR9814035A (fr)
CA (1) CA2309966A1 (fr)
CO (1) CO4980891A1 (fr)
DZ (1) DZ2649A1 (fr)
EA (1) EA003255B1 (fr)
EE (1) EE04235B1 (fr)
HU (1) HUP0100098A3 (fr)
ID (1) ID24933A (fr)
IL (2) IL136122A0 (fr)
IS (1) IS5482A (fr)
MY (1) MY120461A (fr)
NO (1) NO20002450L (fr)
NZ (1) NZ504420A (fr)
OA (1) OA11464A (fr)
PL (1) PL194597B1 (fr)
SA (1) SA98190747B1 (fr)
SK (1) SK286040B6 (fr)
TR (1) TR200001262T2 (fr)
TW (1) TW585766B (fr)
UY (1) UY25247A1 (fr)
WO (1) WO1999025363A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE041842T2 (hu) 2002-06-14 2019-05-28 Toyama Chemical Co Ltd Gyógyászati készítmény agymûködés javítására
JP2005534710A (ja) * 2002-08-07 2005-11-17 ノバルティス アクチエンゲゼルシャフト Ａｐｏｅ遺伝子型を基準とした痴呆を処置するための方法
CN1520818A (zh) * 2003-02-09 2004-08-18 ɽ����Ҷ��Ȼҩ���о��������޹�˾ 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物
MX2007007836A (es) 2004-12-27 2007-08-20 Eisai R&D Man Co Ltd Metodo para estabilizar un farmaco anti-demencia.
RU2692258C2 (ru) 2014-01-31 2019-06-24 Когнишн Терапьютикс, Инк. Композиции изоиндолина и способы лечения нейродегенеративного заболевания
DK3634394T3 (da) 2017-05-15 2026-03-02 Cognition Therapeutics Inc Sammensætninger til behandling af neurogenerative sygdomme
KR102224918B1 (ko) 2018-03-20 2021-03-09 (주)인벤티지랩 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법
WO2019182319A1 (fr) * 2018-03-20 2019-09-26 (주)인벤티지랩 Procédé de préparation de composition pharmaceutique de prévention ou de traitement de maladies associées au trouble cognitif, et composition pharmaceutique de prévention ou de traitement de maladies associées au trouble cognitif, préparée par le procédé de préparation
CN109265391B (zh) * 2018-11-13 2021-11-19 枣庄学院 联苯多取代1,2,5,6-四氢吡啶化合物及其合成方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5453428A (en) * 1991-02-14 1995-09-26 The Mount Sinai School Of Medicine Of The City Of New York Method and composition for the treatment of apathy-amotivation syndrome
ES2244968T3 (es) * 1995-03-06 2005-12-16 Interneuron Pharmaceuticals Incorporated Reduccion del volumen de infarto usando citocolina.
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines

Also Published As

Publication number Publication date
CN1285742A (zh) 2001-02-28
EP1030671A1 (fr) 2000-08-30
DZ2649A1 (fr) 2004-12-28
BR9814035A (pt) 2000-09-26
TW585766B (en) 2004-05-01
CA2309966A1 (fr) 1999-05-27
BG64819B1 (bg) 2006-05-31
UY25247A1 (es) 2001-05-31
EE200000290A (et) 2001-06-15
AU1160999A (en) 1999-06-07
KR100599350B1 (ko) 2006-07-12
OA11464A (en) 2003-11-18
CO4980891A1 (es) 2000-11-27
NZ504420A (en) 2003-08-29
PL194597B1 (pl) 2007-06-29
SK286040B6 (sk) 2008-01-07
IL136122A (en) 2006-07-05
EA200000412A1 (ru) 2000-12-25
KR20010032099A (ko) 2001-04-16
NO20002450D0 (no) 2000-05-11
JP2001523642A (ja) 2001-11-27
EA003255B1 (ru) 2003-02-27
SA98190747B1 (ar) 2006-11-04
BG104428A (en) 2001-08-31
TR200001262T2 (tr) 2001-01-22
IS5482A (is) 2000-05-09
SK7112000A3 (en) 2000-10-09
EE04235B1 (et) 2004-02-16
HUP0100098A2 (hu) 2001-07-30
MY120461A (en) 2005-10-31
IL136122A0 (en) 2001-05-20
NO20002450L (no) 2000-07-14
PL340500A1 (en) 2001-02-12
WO1999025363A1 (fr) 1999-05-27
ID24933A (id) 2000-08-31
HUP0100098A3 (en) 2001-12-28
AU743228B2 (en) 2002-01-24

Similar Documents

Publication Publication Date Title
JP2006512417A5 (fr)
CN1268050A (zh) 用于组合哌啶子基烷醇－减充血剂的药物组合物
CN1481241A (zh) 阿洛地平和贝那普利/苯那普利拉的治疗组合
JP5523706B2 (ja) 新規投薬配合物
CN1243540C (zh) 用于治疗阿尔茨海默氏型老年性痴呆的活性组分的组合
JPH08501562A (ja) 光学的に純粋な（＋）セチリジンを用いたアレルギー疾患の治療のための方法および組成
CN1674903A (zh) 经鼻吸收用组合物
HK1041226A1 (zh) 治療胃-食管返流性疾病的方法和組合物
JP5386478B2 (ja) パーキンソン病に伴う運動不全の治療のための４−シクロプロピルメトキシ−ｎ−（３，５−ジクロロ−１−オキシドピリジン−４−イル）−５−（メトキシ）ピリジン−２−カルボキサミドの使用
US20050148614A1 (en) Combination of active ingredients for the treatment of senile dementia of the Alzheimer type
EP1615641A1 (fr) Combinaisons de paroxetine et de 2-(r)-(4-fluoro-2-methyl-phenyl)-4-(s)-((8as)-6-oxo-hexahydro-pyrrolo 1,2-a]-pyrazin-2-yl)-piperidine-1-acide carboxylique 1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide utilisees dans le traitement de la depression et/ou de l'anxiete
TWI844074B (zh) 氯胺酮衍生物之醫藥組成物及口服劑型
JP2002504134A (ja) 疼痛を治療するためのドラフラジン類似体の使用
CN1348372A (zh) 药物用途
CA2559493A1 (fr) Composition pharmaceutique combinee concue pour inhiber le declin de fonctions cognitives
JP5386476B2 (ja) 頭蓋外傷の治療のための４−シクロプロピルメトキシ−ｎ−（３，５−ジクロロ−１−オキシド−４−ピリジン−４−イル）−５−（メトキシ）ピリジン−２−カルボキサミドの使用
EP1734940B1 (fr) Combinaisons de deramciclane et d'opioides destines a l'utilisation analgesique
CN1297448A (zh) 帕罗西汀抗坏血酸盐
JP2012515764A (ja) 非ステロイド系抗炎症薬およびコルチコシド誘導体を含有する有効成分の新規な組み合わせ
CZ20001734A3 (cs) Farmaceutická kompozice a její použití
BRPI0613281A2 (pt) combinação terapêutica contendo um bloqueador de receptor nmda e uma substáncia analgésica e narcótica
CN1784233A (zh) 用于治疗神经变性的甘氨酸/nmda拮抗剂和速激肽nk－1受体拮抗剂的组合
HK1156248A (en) Therapeutic uses of compounds having combined sert, 5-ht3, and 5-ht1a activity
HK1064601B (en) Pharmaceutical compositions comprising amlodipine maleate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee